EVUSHELD 150 mg + 150 mg solution for injection

DRUG3 trials

Sponsors

AstraZeneca AB, National Institute For Infectious Diseases Lazzaro Spallanzani, Stichting Amsterdam UMC

Conditions

COVID-19Covid-19 infectionSARS-CoV-2 infection

Phase 3

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

CompletedCTIS2024-512554-15-00

AstraZeneca ABCOVID-19

Start: 2023-06-21End: 2025-02-07Target: 533Updated: 2025-02-28

Phase 4

Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies

Not yet recruitingCTIS2024-514071-17-00

National Institute For Infectious Diseases Lazzaro SpallanzaniCovid-19 infection

Target: 150Updated: 2025-01-14

TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2

CompletedCTIS2024-515263-60-00

Stichting Amsterdam UMCSARS-CoV-2 infection

Start: 2024-11-22End: 2025-05-25Target: 400Updated: 2024-11-22